The recognition of the predictive value of estrogen receptor (ER) expression for benefit from adjuvant endocrine therapy (ET) following breast cancer resection led to the widespread recommendation of ET to all patients with ER-positive tumors. This evidence concerns the gene ESR1 and breast cancer.